Shares of G1 THERAPEUTICS (NASDAQ:GTHX) fell 0.8% during mid-day trading on Monday . The company traded as low as $18.50 and last traded at $20.75. 25,400 shares were traded during mid-day trading, a decline of 70% from the average session volume of 83,814 shares. The stock had previously closed at $20.59.
A number of brokerages recently issued reports on GTHX. Zacks Investment Research lowered shares of G1 THERAPEUTICS from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Cowen and Company restated a “buy” rating on shares of G1 THERAPEUTICS in a research note on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $29.75.
Institutional investors have recently added to or reduced their stakes in the business. RA Capital Management LLC acquired a new position in G1 THERAPEUTICS in the second quarter worth $46,813,000. Laurion Capital Management LP acquired a new position in G1 THERAPEUTICS in the second quarter worth $3,488,000. Victory Capital Management Inc. acquired a new position in G1 THERAPEUTICS in the second quarter worth $889,000. Hillhouse Capital Management Ltd. acquired a new position in G1 THERAPEUTICS in the second quarter worth $7,848,000. Finally, FMR LLC acquired a new position in G1 THERAPEUTICS in the second quarter worth $34,093,000. 35.28% of the stock is owned by hedge funds and other institutional investors.
About G1 THERAPEUTICS
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 THERAPEUTICS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 THERAPEUTICS and related companies with MarketBeat.com's FREE daily email newsletter.